Patient P-01505
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
69%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −21% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 55 GI-04 recommended — GI Support Protocol GI-04
- Day 56 Patient accepted — Started GI-04 in the companion
- Day 64 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 70 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 49.
Primary contributors, last 14 days
- GI instability+6
- Inflammatory activity+6
- Toxicity+6
- Nutritional resilience-5
- Treatment adherence+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −21%
- GI Support Protocol GI-04Day 55Result: symptom burden −19%
LIFE OS recommendation
Monitoring Escalation ME-01
83%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 52 and rising
- WearableSleep 5.2 h, below personal baseline
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 56
- Autonomic recovery ↑45
- WearableResting HR 79 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 48/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 5.5 h
- Steps
- 7,272
- Resting HR
- 77 bpm
Daily log: GI score 52, nutritional resilience 43, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01307 | 56% | S14 | GI-04 | improved | 43 |
| P-01356 | 56% | S14 | GI-04 | improved | 42 |
| P-01458 | 54% | S14 | GI-04 | improved | 44 |
| P-01436 | 53% | S14 | GI-04 | improved | 38 |
| P-01559 | 53% | S06 | GI-04 | improved | 42 |
| P-01556 | 52% | S14 | GI-04 | improved | 44 |
| P-01603 | 52% | S14 | GI-04 | improved | 40 |
| P-01781 | 52% | S14 | NP-02 | improved | 45 |
| P-01486 | 51% | S18 | GI-04 | improved | 47 |
| P-01389 | 50% | S14 | SC-12 | improved | 46 |
| P-01570 | 50% | S14 | SC-12 | improved | 46 |
| P-01713 | 50% | S04 | GI-04 | improved | 46 |